WHO ICTRP trial
Optimising adalimumab treatment in psoriasis with concomitant methotrexate.
EUCTR2013-004918-18-BE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2013-004918-18-BE |
|---|---|
| Public title | Optimising adalimumab treatment in psoriasis with concomitant methotrexate. |
| Scientific title | Optimising adalimumab treatment in psoriasis with concomitant methotrexate. - OPTIMAP |
| Primary sponsor | Ghent University Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Belgium;Netherlands |
| Conditions | psoriasis MedDRA version: 20.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] |
| Interventions | Trade Name: LEDERTREXATE 2,5 mg tabletten Product Name: METHOTREXATE Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Aug 4, 2015 |
| Target size | 100 |
| Secondary IDs | OPTIMAP;2013-004918-18-NL |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: